Drug Overdose - Pipeline Review, H2 2019

Published by Global Markets Direct on 18th November 2019 | Ref: 1464132 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Drug Overdose - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H2 2019, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 1, 3, 5, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).

- The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Drug Overdose - Overview

Drug Overdose - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Overdose - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Overdose - Companies Involved in Therapeutics Development

Adamis Pharmaceuticals Corp

Adapt Pharma Ltd

Amphastar Pharmaceuticals Inc

Crossject SA

Fab’entech SA

Icure Pharmaceutical Inc

Insys Therapeutics Inc

iQure Pharma Inc

Klaria Pharma Holding AB

Mucodel Pharma LLC

Opiant Pharmaceuticals Inc

Orexo AB

PledPharma AB

ResQ Pharma Inc

Worphmed Srl

Drug Overdose - Drug Profiles

Antibody for Drug Overdose, Opioid Addiction and Poisoning - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

drinabant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iQ-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPNT-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

physostigmine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Drug Overdose and Drug Toxicity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Alzheimer's Disease and Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Drug Overdose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug Overdose - Dormant Projects

Drug Overdose - Discontinued Products

Drug Overdose - Product Development Milestones

Featured News & Press Releases

Nov 04, 2019: Adamis Pharmaceuticals provides regulatory update for its higher dose Naloxone Pre-Filled Syringe

Oct 08, 2019: Adamis Pharmaceuticals announces presentation of ZIMHI data at IHV Scientific Meeting

Sep 26, 2019: Adamis Pharmaceuticals announces presentation pertaining to its high dose naloxone product candidate at IHV Scientific Meeting

Sep 03, 2019: Adamis Pharmaceuticals provides update for Naloxone product candidate

Aug 07, 2019: Northwest Territories makes NARCAN (naloxone) nasal spray available to all residents for free of charge in response to the opioid crisis

Jul 03, 2019: FDA accepts new drug application for insys therapeutics naloxone nasal spray for the emergency treatment of known or suspected opioid overdose

Jun 27, 2019: Adamis Pharmaceuticals provides update on litigation with kaleo

Jun 11, 2019: Adamis Pharmaceuticals provides update on its higher dose Naloxone injection product

May 21, 2019: Adamis Pharmaceuticals announces patent litigation regarding its higher dose Naloxone Injection Product

May 14, 2019: Adamis Pharmaceuticals announces conditional acceptance by FDA of proprietary name for higher dose Naloxone product

Apr 08, 2019: Opiant Pharmaceuticals announces publication of clinical pharmacokinetic data supporting potential of OPNT003, nasal nalmefene, for treatment of synthetic opioid overdose

Apr 01, 2019: Study finds vast differences in ease-of-use for Naloxone delivery methods

Apr 01, 2019: Opiant Pharmaceuticals announces award of second tranche of approximately .0 million from National Institutes of Health Grant for development of OPNT003, nasal nalmefene, for treatment of opioid overdose

Mar 25, 2019: INSYS Therapeutics to present poster of pharmacokinetic study of Naloxone novel nasal spray at The College on Problems of Drug Dependence Annual Scientific Meeting

Mar 14, 2019: Adamis Pharmaceuticals announces FDA acceptance for review of the New Drug Application of its higher dose naloxone injection product candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1464132 | GMDHC11495IDB

Number of Pages

77

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Research & Data Services
06-02-2017

$680 USD

Published by StratisticsMRC
01-01-2017

$4,150 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Drug Overdose - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.